Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 HKD | +7.69% | +10.24% | -4.11% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.11% | 168M | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+53.61% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+4.57% | 8.84B | |
-2.11% | 7.93B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Announces Resignation of Wei Fu as Non-Executive Director